Alternatively, FASN is a crucial liver enzyme for lipid homeostasis and triglyceride synthesis [46], and PNPLA3 is a marker that is pathologically characterized by the regulation of lipogenesis in obesity, nonalcoholic fatty liver disease, and cardiovascular disease [33]. Here, FASN is linked to metabolic dysfunction-associated steatotic liver disease.